Toxicity prevention with amifostine in pediatric osteosarcoma patients treated with cisplatin and doxorubicin

Pediatric Hematology and Oncology

Volumn 24, Issue 6, 2007, Pages 403-408

  Gallegos Castorena, Sergio ^a,e   Martínez Avalos, Armando ^b   Mohar Betancourt, Alejandro ^c   Guerrero Avendaño, Guadalupe ^d   Zapata Tarrés, Martha ^a   Medina Sansón, Aurora ^a  

^a HOSPITAL INFANTIL DE MÉXICO FEDERICO GÓMEZ   (Mexico)

^b INSTITUTO NACIONAL DE PEDIATRÍA   (Mexico)

^c INSTITUTO NACIONAL DE CANCEROLOGÍA   (Mexico)

^d SECRETARÍA DE SALUD   (Mexico)

^e HOSPITAL CIVIL DE GUADALAJARA FRAY ANTONIO ALCALDE   (Mexico)

Author keywords

Amifostine; Chemotherapy related toxicity; Osteosarcoma

Indexed keywords

AMIFOSTINE; CISPLATIN; DEXAMETHASONE; DOXORUBICIN; ONDANSETRON;

ADOLESCENT; ARTICLE; CANCER CHEMOTHERAPY; CARDIOTOXICITY; CELL PROTECTION; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; MALE; METASTASIS; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEPHROTOXICITY; OSTEOSARCOMA; OTOTOXICITY; PEDIATRICS; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD;

ADOLESCENT; AMIFOSTINE; ANTIEMETICS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE NEOPLASMS; CALCIUM GLUCONATE; CHILD; CISPLATIN; DOXORUBICIN; FEMALE; HEARING LOSS; HEART DISEASES; HUMANS; HYPOCALCEMIA; INFUSIONS, INTRA-ARTERIAL; INFUSIONS, INTRAVENOUS; KIDNEY DISEASES; MALE; NEOADJUVANT THERAPY; ONDANSETRON; OSTEOSARCOMA; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; VOMITING;

EID: 34548142624     PISSN: 08880018     EISSN: 15210669     Source Type: Journal    
DOI: 10.1080/08880010701451244     Document Type: Article

References (17)

1. Kurbacher CM, Mallmann PK. Chemoprotection in anticancer therapy: the emerging role of amifostine. Anticancer Res. 1998;18(3C):2203-2210.
2. Schuchter LM. Exploration of paltinum-based dose intensive chemotherapy strategies with amifostine. Eur J Cancer. 1996;32A(S4):S40-S42.
3. Budd GT, Ganapathi R, Bukowski RM, et al. Clinical effects of amifostine in patients treated with carboplatin. Eur J Cancer. 1996;32A(S4):43-45.
4. Capizzi RL. The preclinical aspects for broad spectrum selective cytoprotection of normal tissues from cytotoxic therapies by amifostine. Semin Oncol. 1999;26(2)(S7):3-21.
5. Calabro-Jones PM, Fahey RC, Smoluk GD, et al. Alkaline phosphatase promotes radioprotection and acumulation of WR 1065 in V79-171 cells incubated in medium containing WR 2721. Int J Radiat Biol. 1985;47:23-27.
6. Utley JF, Seaver N, Newton GL, et al. Pharmacokinetics of WR-1065 in mouse tissue following treatment with WR 2721. Int J Radiat Oncol Biol Phys. 1984;10:1525-1528.
7. Yang JL, Fernandes DJ, Speicher L, et al. Biochemical determinants of the cytoprotective effect of amifostine. Proc Am Assoc Cancer Res. 1995;36:290.
8. Van Der Vjigh WJF, Peters GJ. Protection of lnormal tissues from the cytotoxic effects of chemotherapy and radiation by amisfostine (ethyol): preclinical aspects. Semin Oncol. 1994;21(Suppl 11):2-7.
9. Capizzi RL. Protection of normal tissues from the cytotoxic effects of chemotherapy by amifostine (ethyol): clinical experiences. Semin Oncol. 1994;21(Suppl 11):8-15.
10. Glover DJ, Glick JH, Weiter C, et al. WR-2721 protects against the hematologic toxicity of cyclophosphamide: a controlled phase II trial. J Clin Oncol. 1986;4:584-588.
11. Glover DJ, Glick JH, Weiler C, et al. WR-2721 and high dose cisplatin: an active combination on the treatment of metastasic melanoma. J Clin Oncol. 1987(5):574-578.
12. Chuang VP, Benjamin R, Jaffe N, et al. Radiographic and angiographic changes in osteosarcoma after intraarterial chemotherapy. AJR. 1982;139:1065-1069.
13. Jaffe N. Pediatric osteosarcoma: treatment of the primary tumor with intraarterial cis-diamminedichloroplatinum-II (CDP): advantages, disadvantages, and controversial issues. Cancer Treat Res. 1993;62:75-84.
14. Petrilli AS, Oliveira DT, Ginani VC, et al. Use of amifostine in the therapy of osteosarcoma in children and adolescents. J Pediatr Hematol Oncol. 2002;24:188-191.
15. Gilmer Knight KR, Kraemer DF, Neuwelt EA. Ototoxicity in children receiving platinum chemotherapy: underestimating a common occurring toxicity that may influence academic and social development. J Clin Oncol. 2005;23:8588-8596.
16. Marina N, Chang KW, Malogolowkin M, et al. Amifostine does not protect against the ototoxicity of high-dose cisplatin combined with etoposide and bleomycin in pediatric germ-cell tumors: a Childrens Oncology Group study. Cancer. 2005;104:841-847.
17. Glick JH, Kemp G, Rose P, et al. A randomized trial of cyclophosphamide and cisplatin ± amifostine in the treatment of advanced epithelial ovarian cancer. Proc Assoc Clin Oncol. 1994;13:432.